Skip to Content
Merck
All Photos(1)

Key Documents

SAB4200047

Sigma-Aldrich

Anti-BRD7 antibody, Rat monoclonal

clone BRM 2D3, purified from hybridoma cell culture

Synonym(s):

Anti-BP75, Anti-Bromodomain containing 7, Anti-CELTIX1, Anti-NAG4, Monoclonal Anti-BRD7 antibody produced in rat

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rat

conjugate

unconjugated

antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies

clone

BRM 2D3, monoclonal

form

buffered aqueous solution

mol wt

antigen ~80 kDa

species reactivity

rat, mouse, monkey, human, bovine, canine

packaging

antibody small pack of 25 μL

technique(s)

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: 0.5-1.0 μg/mL using HeLa cells extract

isotype

IgG2a

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... BRD7(29117)

General description

Monoclonal Anti-BRD7 (rat IgG2a isotype) is derived from the hybridoma BRM 2D3 produced by the fusion of mouse myeloma cells (P3X63Ag8.653) and splenocytes from rat immunized with a fusion protein expressing a fragment of human BRD7. Bromodomain containing (BRD7) is a novel bromodomain gene.

Application

Monoclonal Anti-BRD7 antibody produced in rat has been used in several immunochemical techniques including
  • immunoblotting
  • immunoprecipitation
  • immunocytochemistry

Biochem/physiol Actions

Bromodomain containing (BRD7) inhibits cell growth and cell cycle progression by transcriptional regulation of some cell cycle-related genes as well as some important molecules involved in ras/mitogen-activated protein kinase(MEK)/extracellular-signal-regulated kinase (ERK) and retinoblastoma tumor suppressor protein (RB)/ E2 factor (E2F) pathways. Its transcriptional down regulation has been shown to be critical to the pathogenesis of nasopharyngeal carcinoma (NPC). Specifically, DNA methylation decreases the expression of BRD7 in NPC cells. Furthermore, DNA methylation of BRD7 promoter is increased in the tumor and in matched blood samples from NPC patients than in blood samples from healthy individuals. Therefore, it has been suggested that DNA methylation of BRD7 promoter might act as a potential diagnostic marker in NPC.

Physical form

Solution in 0.01M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells
Liu H, et al.
BMC Cancer, 8(1), 253-253 (2008)
The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain
Cong P, et al.
Journal of Cellular Biochemistry, 97(4), 882-892 (2006)
Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis
Chou J, et al.
Head & Neck, 30(7), 946-963 (2008)
Junichi Yamamoto et al.
Nature chemical biology, 16(11), 1208-1217 (2020-09-23)
The immunomodulatory drug (IMiD) thalidomide and its derivatives lenalidomide and pomalidomide are therapeutic agents used in the treatment of multiple myeloma. Although pomalidomide offers considerable clinical benefits to patients with lenalidomide-resistant multiple myeloma, the molecular mechanisms underlying its superior efficacy

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service